A 72-year-old woman with a history of paroxysmal atrial fibrillation, hypertension, and type 2 diabetes mellitus is seen in the outpatient clinic. She has had 3 episodes of AF in the past 6 months, each lasting 4–8 hours and self-terminating. She is currently on metoprolol 50 mg twice daily for rate control and aspirin 75 mg daily. She denies syncope, chest pain, or dyspnea. Blood pressure is 136/84 mmHg, HR 78 bpm (sinus rhythm). Echocardiography shows normal LV function and no structural abnormality. What is the most appropriate next step in her management?

Explanation

## Clinical Assessment This patient has **paroxysmal atrial fibrillation** with the following key features: - Age 72 years - Hypertension - Type 2 diabetes mellitus - 3 AF episodes in 6 months (recurrent, symptomatic) - Normal LV function and no structural heart disease - Currently on rate control only (metoprolol) - On aspirin monotherapy ## Stroke Risk Stratification: CHA~2~DS~2~-VASc Score **Key Point:** Anticoagulation decisions in AF are driven by **stroke risk**, not by AF burden or symptoms. | Factor | Points | |--------|--------| | **C**ongestive heart failure | 1 | | **H**ypertension | 1 | | **A**ge ≥75 years | 2 | | **A**ge 65–74 years | 1 | | **D**iabetes mellitus | 1 | | **S**troke/TIA/thromboembolism | 2 | | **V**ascular disease | 1 | | **A**ge ≥65 years (female) | 1 | | **Sc**ex category (female) | 1 | **This patient's CHA~2~DS~2~-VASc score:** - Hypertension: 1 point - Age 72 (65–74): 1 point - Diabetes: 1 point - Female sex: 1 point - **Total: 4 points → HIGH STROKE RISK** **High-Yield:** Per 2019 AHA/ACC and 2020 ESC guidelines: - **CHA~2~DS~2~-VASc ≥2 in men or ≥3 in women → Anticoagulation is recommended** - This patient scores 4 → **Anticoagulation is mandatory** - Aspirin alone is **inadequate** for stroke prevention in AF with CHA~2~DS~2~-VASc ≥2 ## Why Warfarin (or DOAC) Now? **Clinical Pearl:** Anticoagulation is **independent of**: - AF burden (paroxysmal vs. persistent) - Symptom severity - LV function (normal EF does not reduce stroke risk) - Rate control success All patients with AF and CHA~2~DS~2~-VASc ≥2 (or ≥3 in women) require anticoagulation, regardless of whether they undergo rhythm control or rate control. **Warfarin vs. DOACs:** - Both are acceptable first-line agents - Warfarin: INR target 2–3 for non-valvular AF - DOACs (apixaban, dabigatran, edoxaban, rivaroxaban): preferred in many guidelines due to: - No INR monitoring - More predictable pharmacokinetics - Lower intracranial hemorrhage risk - Choice depends on renal function, drug interactions, and patient preference ## Why Not the Other Options? **Continue current therapy:** Aspirin monotherapy is **inadequate** for stroke prevention in AF with high CHA~2~DS~2~-VASc score. Continuing without anticoagulation exposes the patient to unacceptable stroke risk (approximately 4–6% annual stroke risk with CHA~2~DS~2~-VASc = 4). **Flecainide:** A Class IC antiarrhythmic for rhythm control. Indications: - Paroxysmal AF with recurrent episodes (this patient qualifies) - Structurally normal heart (this patient has normal EF and no structural disease) However, **flecainide is NOT indicated as the next step** because: 1. Anticoagulation takes priority (stroke prevention is the primary goal) 2. Flecainide is a secondary consideration for symptom reduction 3. The patient is already on rate control; rhythm control is optional for paroxysmal AF with infrequent episodes **Amiodarone:** Reserved for: - Symptomatic AF refractory to other antiarrhythmics - Hemodynamically unstable AF - AF with structural heart disease or reduced EF This patient has infrequent episodes (3 in 6 months) and normal LV function, making amiodarone excessive and exposing her to serious toxicity (thyroid, pulmonary, hepatic, proarrhythmia). ## Management Algorithm ```mermaid flowchart TD A[AF Diagnosis]:::outcome --> B{Calculate CHA2DS2-VASc}:::decision B -->|Score ≥2 men or ≥3 women| C[Initiate Anticoagulation]:::action B -->|Score 0-1| D[Aspirin or no therapy]:::action C --> E{Symptomatic/Frequent Episodes?}:::decision E -->|Yes| F[Consider Rhythm Control]:::action E -->|No| G[Rate Control Alone]:::action F --> H[Flecainide/Sotalol if structurally normal]:::action G --> I[Beta-blocker or CCB]:::action ```